S**upplementary Table S5.** Treatment-Related Adverse Events

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| AEs *n (%)* | |  | Anlotinib | Immunotherapy | A+P combination therapy | c2 | *P* |
| General condition | |  |  |  |  |  |  |
|  | Fatigue | 53 (37.3%) | 20 | 12 | 21 | 0.272 | 0.873 |
|  | Anorexia symptoms | 45 (31.7%) | 20 | 9 | 16 | 0.770 | 0.681 |
|  | Headache/Dizziness | 47 (33.1%) | 17 | 12 | 18 | 1.148 | 0.563 |
|  | Neutropenia | 34 (23.9%) | 14 | 5 | 15 | 0.926 | 0.629 |
| Gastrointestinal system | |  |  |  |  |  |  |
|  | Diarrhea | 15 (10.6%) | 7 | 4 | 4 | 1.301 | 0.522 |
|  | Oral mucositis | 13 (9.2%) | 7 | 3 | 3 | 1.841 | 0.398 |
|  | Vomiting | 11 (7.7%) | 8 | 1 | 2 | 5.533 | 0.063 |
| Hepatobiliary system | |  |  |  |  |  |  |
|  | Transaminitis | 30 (21.1%) | 9 | 4 | 17 | 4.383 | 0.112 |
| Respiratory system | |  |  |  |  |  |  |
|  | Cough | 28 (19.7%) | 12 | 7 | 9 | 1.017 | 0.601 |
|  | Dyspnea | 5 (3.5%) | 2 | 1 | 2 | 0.001 | 1.000 |
|  | Hemoptysis | 9 (6.3%) | 3 | 3 | 3 | 0.986 | 0.611 |
| Cardiovascular system | |  |  |  |  |  |  |
|  | Hypertension | 27 (19.0%) | 8 | 6 | 13 | 1.398 | 0.497 |
| Skin system | |  |  |  |  |  |  |
|  | Rash | 21 (14.8%) | 10 | 4 | 7 | 0.726 | 0.696 |
|  | Hand-foot syndrome | 18 (12.7%) | 8 | 5 | 5 | 1.462 | 0.481 |
|  | Pruritus | 25 (17.6%) | 11 | 6 | 8 | 0.851 | 0.653 |
| *AEs, adverse events* | |  |  |  |  |  |  |